<p>F M Investments LLC 在最近向美國證券交易委員會提交的 13F 文件中表示，在第三季度將其在 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免費報告) 的股份減少了 10.0%。該機構投資者在季度內出售了 4,731 股後，持有該製藥公司 42,463 股股票。Vertex Pharmaceuticals 佔 F M Investments LLC 投資組合的 0.7%，使其成為該投資組合中第 27 大持倉。截至其最近向美國證券交易委員會提交的文件，F M Investments LLC 在 Vertex Pharmaceuticals 的持股價值為 19,749,000 美元。</p>
<p>獲取 <strong>Vertex Pharmaceuticals</strong> 警報：</p>
<ul>
<li>生物科技股票突破：IBB 關注 Amgen 和 Vertex 的阻力位</li>
</ul>
<p>其他機構投資者和對沖基金最近也對該公司的持倉進行了調整。Northwest Investment Counselors LLC 在第三季度購買了價值 25,000 美元的 Vertex Pharmaceuticals 新股份。Highline Wealth Partners LLC 在第三季度購買了價值 27,000 美元的 Vertex Pharmaceuticals 新股份。GHP Investment Advisors Inc. 在第二季度購買了價值 29,000 美元的 Vertex Pharmaceuticals 新股份。Stephens Consulting LLC 在第二季度購買了價值 31,000 美元的 Vertex Pharmaceuticals 新股份。最後，Founders Capital Management 在第二季度將其在 Vertex Pharmaceuticals 的持倉增加了 50.0%。Founders Capital Management 現在擁有 75 股該製藥公司的股票，價值 35,000 美元，此前在此期間又購買了 25 股。對沖基金和其他機構投資者持有該公司 90.96% 的股份。</p>
<h2>華爾街分析師觀點</h2>
<p>一些股票研究分析師最近對 VRTX 股票發表了看法。HC Wainwright 在 10 月 21 日的研究報告中重申了 &#34;買入&#34; 評級，並設定了 600.00 美元的目標價。Guggenheim 將 Vertex Pharmaceuticals 的目標價從 450.00 美元上調至 558.00 美元，並在 8 月 2 日的研究報告中給予該公司 &#34;買入&#34; 評級。TD Cowen 將 Vertex Pharmaceuticals 的目標價從 450.00 美元上調至 500.00 美元，並在 7 月 23 日的研究報告中給予該公司 &#34;買入&#34; 評級。摩根士丹利在 10 月 1 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 462.00 美元上調至 474.00 美元，並給予該公司 &#34;同等權重&#34; 評級。最後，Scotiabank 在 10 月 16 日的研究報告中開始覆蓋 Vertex Pharmaceuticals 的股票。他們設定了 &#34;行業表現&#34; 評級和 480.00 美元的目標價。三位研究分析師對該股票給予了賣出評級，十位給予了持有評級，十七位給予了買入評級。根據 MarketBeat 的數據，Vertex Pharmaceuticals 目前的共識評級為 &#34;持有&#34;，共識目標價為 492.50 美元。</p>
<ul>
<li>生物科技行業會從滯後者轉變為領導者嗎？</li>
</ul>
<p><strong>查看我們最新的 VRTX 股票分析</strong></p>
<h2>Vertex Pharmaceuticals 股票表現</h2>
<p>VRTX 週五開盤價為 471.12 美元。該公司的市值為 1216 億美元，市盈率為 -232.08，貝塔值為 0.39。Vertex Pharmaceuticals Incorporated 的 1 年最低價為 341.90 美元，1 年最高價為 510.64 美元。該公司的 50 日簡單移動平均線為 474.53 美元，200 日簡單移動平均線為 464.46 美元。該公司的債務與股本比率為 0.02，流動比率為 2.52，速動比率為 2.26。</p>
<ul>
<li>生物科技行業接近突破：第二季度會表現優於市場嗎？</li>
</ul>
<p>Vertex Pharmaceuticals (NASDAQ:VRTX - 獲取免費報告) 最近在 8 月 1 日發佈了季度財報。該製藥公司報告本季度每股收益為（12.83 美元），低於分析師的共識預期（12.54 美元）0.29 美元。該公司本季度的收入為 26.5 億美元，而共識預期為 26.6 億美元。Vertex Pharmaceuticals 的股本回報率為 -2.45%，淨利潤率為 -4.74%。該公司本季度的收入較去年同期增長了 6.1%。在去年同期，該公司每股收益為 3.53 美元。股票分析師預測，Vertex Pharmaceuticals Incorporated 本財年將發佈 -2.04 美元的每股收益。</p>
<h2>內部人士下注</h2>
<p>在 Vertex Pharmaceuticals 的其他新聞中，董事長 Jeffrey M. Leiden 於 8 月 30 日星期五出售了 3,784 股公司股票。股票的平均售價為 499.00 美元，總價值為 1,888,216.00 美元。交易完成後，董事長現在直接持有 9,994 股公司股票，價值 4,987,006 美元。這代表其持股比例下降了 0.00%。該交易已在向美國證券交易委員會（SEC）提交的文件中披露，相關文件可通過此鏈接獲取。相關消息中，首席營銷官 Carmen Bozic 於 8 月 7 日星期三出售了 2,280 股公司股票。股票的平均售價為 476.75 美元，總交易額為 1,086,990.00 美元。交易完成後，首席營銷官現在持有 23,259 股公司股票，價值約 11,088,728.25 美元。這代表其持股比例下降了 0.00%。該銷售已在向證券交易委員會的法律文件中披露，相關文件可通過此鏈接訪問。此外，董事長 Jeffrey M. Leiden 於 8 月 30 日星期五再次出售了 3,784 股公司股票。股票的平均售價為 499.00 美元，總交易額為 1,888,216.00 美元。交易完成後，董事長現在持有 9,994 股公司股票，價值約 4,987,006 美元。這代表其持股比例下降了 0.00%。該銷售的披露信息可在此找到。過去三個月內，內部人士共出售了 6,710 股公司股票，價值 3,298,206 美元。目前，內部人士持有公司股票的比例為 0.20%。</p>
<h2>Vertex Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化（CF）的療法。它為至少 2 歲或以上的 CF 患者銷售 TRIKAFTA/KAFTRIO；為 6 歲或以上的 CF 患者銷售 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者銷售 ORKAMBI；以及為 1 歲或以上的 CF 患者銷售 KALYDECO，適用於使用 ivacaftor 的患者。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Vertex Pharmaceuticals</li>
<li>股息捕捉策略：你需要知道的事項</li>
<li>零售商之戰：誰將勝出？</li>
<li>內幕交易 - 你需要知道的事項</li>
<li>HCA Healthcare：暫時的挫折，長期的實力</li>
<li>複利是如何計算的？</li>
<li>MarketBeat 週報 – 10/28 - 11/1</li>
</ul>
<p><strong>想看看其他對 VRTX 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免費報告) 的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<p>→ 我們在 2016 年推薦了 Nvidia，現在我們推薦這個……（來自 Porter &amp; Company）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDEzMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDEzMQ"/></p>
<h2>你現在應該投資 1,000 美元在 Vertex Pharmaceuticals 嗎？</h2>
<p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Vertex Pharmaceuticals 並不在名單上。</p>
<p>雖然 Vertex Pharmaceuticals 目前在分析師中獲得了 &#34;持有&#34; 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

福泰制藥

<p>F M Investments LLC 在第三季度減少了對 Vertex Pharmaceuticals (NASDAQ:VRTX) 的持股比例，下降了 10%，目前持有 42,463 股，價值 7,749,000 美元。其他機構投資者也調整了他們的持倉。分析師對該股票的評級意見不一，普遍評級為 “持有”，目標價格為 329.50 美元。Vertex 最近的財報顯示每股虧損 0.83 美元，未達到預期，收入為 6.5 億美元。該股票開盤價為 329.12 美元，市值為 836 億美元，市盈率為 -232.08</p>

<p>F M Investments LLC lowered its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 10.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 42,463 shares of the pharmaceutical company's stock after selling 4,731 shares during the quarter. Vertex Pharmaceuticals accounts for 0.7% of F M Investments LLC's investment portfolio, making the stock its 27th biggest position. F M Investments LLC's holdings in Vertex Pharmaceuticals were worth $19,749,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>F M Investments LLC 在最近向美國證券交易委員會提交的 13F 文件中表示，在第三季度將其在 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免費報告) 的股份減少了 10.0%。該機構投資者在季度內出售了 4,731 股後，持有該製藥公司 42,463 股股票。Vertex Pharmaceuticals 佔 F M Investments LLC 投資組合的 0.7%，使其成為該投資組合中第 27 大持倉。截至其最近向美國證券交易委員會提交的文件，F M Investments LLC 在 Vertex Pharmaceuticals 的持股價值為 19,749,000 美元。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Vertex Pharmaceuticals</strong> 警報：</p>
</div><ul>
<li>Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技股票突破：IBB 關注 Amgen 和 Vertex 的阻力位</li>
</ul>
</div><p>Other institutional investors and hedge funds have also recently made changes to their positions in the company. Northwest Investment Counselors LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter valued at $25,000. Highline Wealth Partners LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter valued at $27,000. GHP Investment Advisors Inc. purchased a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $29,000. Stephens Consulting LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $31,000. Finally, Founders Capital Management raised its position in Vertex Pharmaceuticals by 50.0% in the 2nd quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company's stock worth $35,000 after purchasing an additional 25 shares during the period. Hedge funds and other institutional investors own 90.96% of the company's stock.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金最近也對該公司的持倉進行了調整。Northwest Investment Counselors LLC 在第三季度購買了價值 25,000 美元的 Vertex Pharmaceuticals 新股份。Highline Wealth Partners LLC 在第三季度購買了價值 27,000 美元的 Vertex Pharmaceuticals 新股份。GHP Investment Advisors Inc. 在第二季度購買了價值 29,000 美元的 Vertex Pharmaceuticals 新股份。Stephens Consulting LLC 在第二季度購買了價值 31,000 美元的 Vertex Pharmaceuticals 新股份。最後，Founders Capital Management 在第二季度將其在 Vertex Pharmaceuticals 的持倉增加了 50.0%。Founders Capital Management 現在擁有 75 股該製藥公司的股票，價值 35,000 美元，此前在此期間又購買了 25 股。對沖基金和其他機構投資者持有該公司 90.96% 的股份。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of equities research analysts have recently weighed in on VRTX shares. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $600.00 target price on shares of Vertex Pharmaceuticals in a research note on Monday, October 21st. Guggenheim lifted their target price on shares of Vertex Pharmaceuticals from $450.00 to $558.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, August 2nd. TD Cowen lifted their target price on shares of Vertex Pharmaceuticals from $450.00 to $500.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, July 23rd. Morgan Stanley lifted their price target on shares of Vertex Pharmaceuticals from $462.00 to $474.00 and gave the company an &#34;equal weight&#34; rating in a research report on Tuesday, October 1st. Finally, Scotiabank assumed coverage on shares of Vertex Pharmaceuticals in a research report on Wednesday, October 16th. They set a &#34;sector perform&#34; rating and a $480.00 price target for the company. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $492.50.</p>
<div class="lb-trans"><p>一些股票研究分析師最近對 VRTX 股票發表了看法。HC Wainwright 在 10 月 21 日的研究報告中重申了 &#34;買入&#34; 評級，並設定了 600.00 美元的目標價。Guggenheim 將 Vertex Pharmaceuticals 的目標價從 450.00 美元上調至 558.00 美元，並在 8 月 2 日的研究報告中給予該公司 &#34;買入&#34; 評級。TD Cowen 將 Vertex Pharmaceuticals 的目標價從 450.00 美元上調至 500.00 美元，並在 7 月 23 日的研究報告中給予該公司 &#34;買入&#34; 評級。摩根士丹利在 10 月 1 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 462.00 美元上調至 474.00 美元，並給予該公司 &#34;同等權重&#34; 評級。最後，Scotiabank 在 10 月 16 日的研究報告中開始覆蓋 Vertex Pharmaceuticals 的股票。他們設定了 &#34;行業表現&#34; 評級和 480.00 美元的目標價。三位研究分析師對該股票給予了賣出評級，十位給予了持有評級，十七位給予了買入評級。根據 MarketBeat 的數據，Vertex Pharmaceuticals 目前的共識評級為 &#34;持有&#34;，共識目標價為 492.50 美元。</p>
</div><ul>
<li>Will the Biotech Sector Shift From Lagger to Leader?</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技行業會從滯後者轉變為領導者嗎？</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Analysis on VRTX</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 VRTX 股票分析</strong></p>
</div><h2>Vertex Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股票表現</h2>
</div><p>VRTX opened at $471.12 on Friday. The firm has a market cap of $121.60 billion, a P/E ratio of -232.08 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a 1-year low of $341.90 and a 1-year high of $510.64. The company has a 50 day simple moving average of $474.53 and a two-hundred day simple moving average of $464.46. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26.</p>
<div class="lb-trans"><p>VRTX 週五開盤價為 471.12 美元。該公司的市值為 1216 億美元，市盈率為 -232.08，貝塔值為 0.39。Vertex Pharmaceuticals Incorporated 的 1 年最低價為 341.90 美元，1 年最高價為 510.64 美元。該公司的 50 日簡單移動平均線為 474.53 美元，200 日簡單移動平均線為 464.46 美元。該公司的債務與股本比率為 0.02，流動比率為 2.52，速動比率為 2.26。</p>
</div><ul>
<li>Biotech Sector Nears Breakout: Will it Outperform in Q2?</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技行業接近突破：第二季度會表現優於市場嗎？</li>
</ul>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share for the quarter, missing analysts' consensus estimates of ($12.54) by ($0.29). The firm had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The business's revenue for the quarter was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.53 earnings per share. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post -2.04 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals (NASDAQ:VRTX - 獲取免費報告) 最近在 8 月 1 日發佈了季度財報。該製藥公司報告本季度每股收益為（12.83 美元），低於分析師的共識預期（12.54 美元）0.29 美元。該公司本季度的收入為 26.5 億美元，而共識預期為 26.6 億美元。Vertex Pharmaceuticals 的股本回報率為 -2.45%，淨利潤率為 -4.74%。該公司本季度的收入較去年同期增長了 6.1%。在去年同期，該公司每股收益為 3.53 美元。股票分析師預測，Vertex Pharmaceuticals Incorporated 本財年將發佈 -2.04 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 3,784 shares of the company's stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $499.00, for a total value of $1,888,216.00. Following the completion of the transaction, the chairman now directly owns 9,994 shares in the company, valued at $4,987,006. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CMO Carmen Bozic sold 2,280 shares of the company's stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $476.75, for a total transaction of $1,086,990.00. Following the completion of the transaction, the chief marketing officer now owns 23,259 shares in the company, valued at approximately $11,088,728.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Jeffrey M. Leiden sold 3,784 shares of the company's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the transaction, the chairman now owns 9,994 shares of the company's stock, valued at approximately $4,987,006. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,710 shares of company stock worth $3,298,206 over the last three months. 0.20% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在 Vertex Pharmaceuticals 的其他新聞中，董事長 Jeffrey M. Leiden 於 8 月 30 日星期五出售了 3,784 股公司股票。股票的平均售價為 499.00 美元，總價值為 1,888,216.00 美元。交易完成後，董事長現在直接持有 9,994 股公司股票，價值 4,987,006 美元。這代表其持股比例下降了 0.00%。該交易已在向美國證券交易委員會（SEC）提交的文件中披露，相關文件可通過此鏈接獲取。相關消息中，首席營銷官 Carmen Bozic 於 8 月 7 日星期三出售了 2,280 股公司股票。股票的平均售價為 476.75 美元，總交易額為 1,086,990.00 美元。交易完成後，首席營銷官現在持有 23,259 股公司股票，價值約 11,088,728.25 美元。這代表其持股比例下降了 0.00%。該銷售已在向證券交易委員會的法律文件中披露，相關文件可通過此鏈接訪問。此外，董事長 Jeffrey M. Leiden 於 8 月 30 日星期五再次出售了 3,784 股公司股票。股票的平均售價為 499.00 美元，總交易額為 1,888,216.00 美元。交易完成後，董事長現在持有 9,994 股公司股票，價值約 4,987,006 美元。這代表其持股比例下降了 0.00%。該銷售的披露信息可在此找到。過去三個月內，內部人士共出售了 6,710 股公司股票，價值 3,298,206 美元。目前，內部人士持有公司股票的比例為 0.20%。</p>
</div><h2>Vertex Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化（CF）的療法。它為至少 2 歲或以上的 CF 患者銷售 TRIKAFTA/KAFTRIO；為 6 歲或以上的 CF 患者銷售 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者銷售 ORKAMBI；以及為 1 歲或以上的 CF 患者銷售 KALYDECO，適用於使用 ivacaftor 的患者。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Battle of the Retailers: Who Comes Out on Top?</li>
<li>Insider Trading - What You Need to Know</li>
<li>HCA Healthcare: Temporary Setbacks, Long-Term Strength</li>
<li>How is Compound Interest Calculated?</li>
<li>MarketBeat Week in Review – 10/28 - 11/1</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Vertex Pharmaceuticals</li>
<li>股息捕捉策略：你需要知道的事項</li>
<li>零售商之戰：誰將勝出？</li>
<li>內幕交易 - 你需要知道的事項</li>
<li>HCA Healthcare：暫時的挫折，長期的實力</li>
<li>複利是如何計算的？</li>
<li>MarketBeat 週報 – 10/28 - 11/1</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding VRTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 VRTX 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免費報告) 的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><p>→ We recommended Nvidia in 2016, now we’re recommending this… (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 我們在 2016 年推薦了 Nvidia，現在我們推薦這個……（來自 Porter &amp; Company）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDEzMQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10131&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Vertex Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Vertex Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Vertex Pharmaceuticals 並不在名單上。</p>
</div><p>While Vertex Pharmaceuticals currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Vertex Pharmaceuticals 目前在分析師中獲得了 &#34;持有&#34; 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

F M Investments LLC 減少了在福泰製藥公司（NASDAQ:VRTX）的持股